PHA Exam 1. Spring 2013

Similar documents
PHA Case Study III (Answers)

PHA Spring First Exam. 8 Aminoglycosides (5 points)

PHA5128 Dose Optimization II Case Study 3 Spring 2013

Name: UFID: PHA Exam 2. Spring 2013

Combined use of calcipotriol solution (SOp.g/ ml) and Polytar liquid in scalp psoriasis.

Reliability Demonstration Test Plan

Dr She Lok, Dr David Greenberg, Barbara Gill, Andrew Murphy, Dr Linda McNamara

PHA 5128 Spring 2000 Final Exam

REGRESSION ASSOCIATION VS. PREDICTION

PHA 5128 Spring 2009 First Exam (Version B)

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

TDM of Aminoglycoside Antibiotics

Going Below the Surface Level of a System This lesson plan is an overview of possible uses of the

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

EXPERIMENT 4 DETERMINATION OF ACCELERATION DUE TO GRAVITY AND NEWTON S SECOND LAW

YOUR VIEWS ABOUT YOUR HIGH BLOOD PRESSURE

Implementation of a planar coil of wires as a sinusgalvanometer. Analysis of the coil magnetic field

EXPERIMENTAL DRYING OF TOBACCO LEAVES

Fall 2005 Economics and Econonic Methods Prelim. (Shevchenko, Chair; Biddle, Choi, Iglesias, Martin) Econometrics: Part 4

Difference in Characteristics of Self-Directed Learning Readiness in Students Participating in Learning Communities

SHC Vancomycin Dosing Guide

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Research into the effect of the treatment of the carpal tunnel syndrome with the Phystrac traction device

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Adolescent Medicine. Management and Referral Guidelines

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

Form. Tick the boxes below to indicate your change(s) of circumstance and complete the relevant sections of this form

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam Fall 2006

Design of a Low Noise Amplifier in 0.18µm SiGe BiCMOS Technology

Chapter 12 Student Lecture Notes 12-1

Determinants of Poverty Status among Broiler Farmers in Calabar Metropolis, Cross River State, Nigeria

AN ANALYSIS OF TELEPHONE MESSAGES: MINIMIZING UNPRODUCTIVE REPLAY TIME

Isolating the Impact of Learning Communities and First-Year Residence Halls on First-Year Student Retention and Success

Lessons from recent studies. João Gonçalves Pereira UCIP DALI

Cattle Finishing Net Returns in 2017 A Bit Different from a Year Ago Michael Langemeier, Associate Director, Center for Commercial Agriculture

MATH 1300: Finite Mathematics EXAM 2 15 March 2017

National Assessment in Sweden. A multi-dimensional (ad)venture

2 Arrange the following angles in order from smallest to largest. A B C D E F. 3 List the pairs of angles which look to be the same size.

Labyrinth Seal Design Optimization Based on Quadratic Regression Orthogonal Experiment

Measuring Cache and TLB Performance and Their Effect on Benchmark Run Times

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

Difficult Heat Illness Problems; EAMC & Rhabdomyolysis

Office of Emergency Services (3055P)

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

Sign up is easy no personal information needed. Reserve your spot today:

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

MATH 1300: Finite Mathematics EXAM 1 15 February 2017

San Raffaele Hospital and Emo Centro Cuore Columbus Milan- Italy

Components Required: Small bread-board to build the circuit on( or just use clip leads directly) 2ea 220pF capacitors 1 ea 1nF 10uH inductor

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

DEVELOPMENT OF A TEST DEVICE FOR THE EVALUATION OF JOURNAL BEARINGS

Design and simulation of the microstrip antenna for 2.4 GHz HM remote control system Deng Qun 1,a,Zhang Weiqiang 2,b,Jiang Jintao 3,c

A e C l /C d. S j X e. Z i

AAOS: American Academy of Orthopaedic Surgeons; AOFAS: American Orthopaedic Foot and Ankle Society; CHI: Catholic Health Initiatives.

Improving the Surgical Ward Round.

MUDRA PHYSICAL SCIENCES

Reliability of fovea palatinea in determining the posterior palatal seal

Percentage of Non-Caucasians in Clinical Trials from 2000 to By Meghanadh Yerram E Special Project

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

FEM Analysis of Welded Spherical Joints Stiffness Fan WANG a, Qin-Kai CHEN b, Qun WANG b, Ke-Wei ZHU b, Xing WANG a

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

A multiple mediator model: Power analysis based on Monte Carlo simulation

Evaluation Of Logistic Regression In Classification Of Drug Data In Kwara State

IS THE IDEAL FILTER REALLY IDEAL: THE USAGE OF FREQUENCY FILTERING AND SPURIOUS CYCLES

Optimize Neural Network Controller Design Using Genetic Algorithm

Localization Performance of Real and Virtual Sound Sources

SBUH Aminoglycoside Dosing Protocol

PHA Final Exam Fall 2001

New Methods for Modeling Reliability Using Degradation Data

Car Taxes and CO 2 emissions in EU. Summary. Introduction. Author: Jørgen Jordal-Jørgensen, COWI

Multiple IV Bolus Dose Administration

Tests on a Single Phase Transformer

TWO REFERENCE japollo LUNAR PARKING - ORBITS / T. P. TIMER. (NASA CR OR rmx OR AD NUMBER) OCTOBER 1965 GODDARD SPACE FLIGHT CENTER

THE CROSS-FLOW DRAG ON A MANOEUVRING SHIP. J. P. HOOFf. MARIN, Wageningen, The Netherlands

Catriona Crossan Health Economics Research Group (HERG), Brunel University

Diabete s & hy p e r te n sio n

The general Concepts of Pharmacokinetics

Company registration number: ROI FRS 105 Demo Client UNAUDITED FINANCIAL STATEMENTS for the year ended 31 January 2018

Emerging Subsea Networks

Published in Public Opinion Quarterly, 39, 1975, Monetary Incentives in Mail Surveys

PHARMONITOR II. Optimisation of aminoglycosides dosage regimen with pharmacokinetics modeling. Pierre Wallemacq

The Monitoring of Machining Inherent

Evaluation of Accuracy of U.S. DOT Rail-Highway Grade Crossing Accident Prediction Models

Chemistry and Technology of Fuels and Oils, Vol. 48, No. 6, January, 2013 (Russian Original No. 6, November December, 2012)

Or-Light Efficiency and Tolerance New-generation intense and pulsed light system

DISCUSSION ON THE TIMEFRAME FOR THE ACHIEVEMENT OF PE14.

NBER WORKING PAPER SERIES HOW DOES COST-SHARING AFFECT DRUG PURCHASES? INSURANCE REGIMES IN THE PRIVATE MARKET FOR PRESCRIPTION DRUGS

Imperfection of Drug Therapy

Time Variation of Expected Returns on REITs: Implications for Market. Integration and the Financial Crisis

Vaccines 2013, 1, ; doi: /vaccines Article. Deanna Kruszon-Moran 1, *, R. Monina Klevens 2 and Geraldine M.

Econometric Analysis of Malnutrition Severity Among Under Five Children in Bangladesh

BSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin

The Leonid 2000 Meteor Shower. Information for spacecraft operators

Comparing Methods for Once Daily Tobramycin Exposure Predictions in Children with Cystic Fibrosis

Why are Virgin Adolescents Worried about Contracting HIV/AIDS? Evidence from Four Sub-Saharan African Countries

Effective Subgrade Coefficients for Seismic Performance Assessment of Pile Foundations

Fusarium vs. Soybean

Transcription:

PHA 5128 Exam 1 Spring 2013 1 Antibiotics (5 points) 2 Body Wight/Pdiatrics (5 points) 3 Rnal Disas (10 points) 4 Aminoglycosids (5 points) 5 Amikacin (10 points) 6 Gntamicin (10 points) 7 Aminoglycosids (5 points) 8 Bioavailability (10 points) 9 Basic Principls (10 points) 10 Basic Principls (5 points) 11 Basic Principls (10 points) 12 Basic Principls (5 points) 13 Antibiotics (5 points) 14 Aminoglycosids (5 points)

Problm 1 (5 points) An antibiotic pharmacokintic bhavior is bst dscribd by a 2-compartmnt modl. Th drug is administrd as an intravnous bolus and its pharmacokintic profil is bst charactrizd by th following quation, C(t) = 20 0.135 t + 18 0.067 t whr th concntration is in mg/l and tim is in hour. Estimat th ara undr th curv and dtrmin whthr th AUC/MIC ratio is gratr than 400 if th MIC against th infction is 2 mg/l. Us th following quation to comput th AUC AUC = A α + B β A. AUC = 432 mg*h/l; AUC/MIC ratio is gratr than 400 B. AUC = 834 mg*h/l; AUC/MIC ratio is gratr than 400 C. AUC = 417 mg*h/l; AUC/MIC ratio is lss than 400 D. AUC = 208 mg*h/l; AUC/MIC ratio is gratr than 400 E. AUC = 417 mg*h/l; AUC/MIC ratio is gratr than 400 AUC = A α + B β = 20 0.135 + 18 = 417 mg h/l 0.067 AUC MIC = 417 2 = 208

Problm 2 (5 points) Which of th following statmnts about body wight ar TRUE? (1) Obs patints may xprinc an ovrdos of a wakly or modratly lipophilic drug compard to a patint with idal body wight if th total body wight basd dosing approach is usd, sinc thy ar poorly distributd in obs patints. (2) Th total body watr (in % of body wight) in nonats is usually smallr than that in adults. (3) Lipophilic drugs tnd to hav a largr volum of distribution whn givn to patints with an incrasd body wight compard to patints with an idal body wight (4) Th plasma protin binding of drugs in nonats is usually lss than in adults. A. 1&2&3 B. 2&4 C. 3&4 D. 1&3&4 E. All th statmnts ar corrct

Problm 3 (10 points) Aftr masuring hr srum cratinin concntration, you calculat th cratinin claranc of a 20 yar old fmal patint (60 kg, 165cm) to b 6 L/h. What is hr srum cratinin concntration? A. 14.12 mg/dl B. 0.85 mg/dl C. 14.12 µg/dl D. 0.85 µg/dl E. Th information providd is not nough to answr th qustion IBW=45+0.9(hight in cm-150)=45+0.9(165-150)=45+13.5=58.5 kg TBW 60 100% 102.6% 120% IBW 58.5 Sinc TBW is lss than 120% of IBW, w should us TBW as dosing wight to calculat cratinin claranc CLcr=6 L/h=100 ml/min Cp cr (140 ag) BW (140 20) 60 0.85 mg dl CL 85 100 85 cr

Problm 4 (5 points) J.C. is a 57 kg fmal patint with mthicillin-rsistant S. aurus infction. Which of th following would b a rcommndd dosing rgimn if th tobramycin plasma concntration was 8mg/L at 8 hours aftr th start of th infusion? Plas assum avrag population PK paramtrs for J.C. and us th nomogram that is givn blow. A. 400mg Q24h B. 500mg Q24h C. 400mg Q36h D. 500mg Q36h E. 400mg Q48h

Problm 5 (10 points) A 9-yar-old boy is hospitalizd with possibl bactrial infction. 500 mg amikacin (IV infusion for 45 min, Q12h) was givn for svral days. Th dosing tim is 8 am and 8 pm. His plasma sampls at stady stat wr analyzd and th rsults ar listd as follows: Tim Concntration 9 am 30 µg/ml 6:30 pm 4 µg/ml Calculat th volum of distribution (round appropriatlty). A. 12 L B. 16 L C. 20 L D. 24 L E. 30 L k C max ln 30 ln Cmin 4 0.212 t 9.5 h 1 t1=0.25h, t2=1.5h C C 30 31.6 g ml 1 max max kt 0.212 0.25 C C g ml kt 2 0.212 1.5 min min 4.0 2.9 Dos Vd 15.9L k T C C kt 0.212 0.75 (1 ) 500 (1 ) kt 0.212 0.75 ( max min ) 0.212 0.75 (31.6 2.9 )

Problm 6 (10 points) A 40 yar old fmal patint, who suffrs from post-surgical wound infction, has bn tratd with gntamicin for svral days. Sh is 5 2 tall and 55 kg wight. Hr srum cratinin is 1.5 mg/dl. Th gntamycin is givn by IV infusion ovr 30 min with dos of 7mg/kg onc daily. Calculat th masurd pak concntration on hour aftr th infusion was startd? (Round appropriatly) A. Cmax=15 mg/l B. Cmax=20 mg/l, C. Cmax=25 mg/l D. Cmax=30 mg/l E. Cmax= 35 mg/l IBW=45+2.3(hight in inchs-60)=45+2.3(62-60)=45+4.6=49.6 kg TBW 55 100% 110.9% 120% IBW 49.6 Sinc TBW is smallr than 120% of IBW, TBW will b usd to calculat cratinin claranc (140 ag) BW (140 40) 55 CL CLcr 43.1ml min 2.6 L h Cp 85 1.5 85 Vd 0.25 L kg 55kg 13.75L k cr CL 2.6 0.189h Vd 13.75 τ=24h and T=0. 5h C 1 Dos 7 55 27.0 mg L 1 1 Vd k T ( ) 13.75 0.189 0.5 ( ) kt 0.189 0.5 1 1 max k 0.189 24 t1=0.5h, C C mg L kt 1 0.189 0.5 max max 27.0 25

Problm 7 (5 points) Which of th following statmnts about aminoglycosids ar TRUE? 1. Th volum of distribution of aminoglycosids is usually 0.25 L. 2. Aminoglycosids ar mostly clard by th kidny. 3. Thraputic drug monitoring is not rcommndd for aminoglycosids. 4. Thr tims daily dosing is highly rcommndd for aminoglycosids. 5. A patint s cratinin claranc can b usd to stimat his total systmic claranc. A. 1&2&5 B. 1&3&4 C. 2&5 D. 1&5 E. All th statmnts ar corrct

Problm 8 (10 points) Basd on th tabl of pharmacokintic paramtrs obtaind aftr a 50 mg dos of drug A, plas calculat th bioavailability of drug A for th thr ag groups Ag group (yars) CL (L/h) T1/2 (h) Oral AUC (mg h/l) 20-39 42.5 21 0.35 40-59 35.7 29 0.47 60-79 26.0 36 0.79 A. F20-39=0.35, F40-59 =0.47, F60-79=0.79 B. F20-39=0.30, F40-59 =0.34, F60-79=0.41 C. F20-39=0.25, F40-59 =0.29, F60-79=0.53 D. F20-39=1, F40-59 =0.84, F60-79=0.61 E. F20-39=0.44, F40-59 =0.59, F60-79=1 Dos F AUC CL F F F AUC CL Dos 0.35 42.5 50 20 39 20 39 AUC CL Dos 0.47 35.7 50 40 59 40 59 AUC CL Dos 0.79 26.0 50 60 79 60 79 0.30 0.34 0.41

Problm 9 (10 points) How will an incras in plasma protin binding affct th claranc (CL), bioavailability (F), and AUC, of a low-xtraction drug? (Plas not that mans no chang) (10 points) A. CL, F, AUC, B. CL, F, AUC C. CL, F, AUC D. CL, F, AUC E. CL, F, AUC Q CL f int u CL Q E Q CL int f u Q CLint f CL f CL u int u CL f Q F CL f Q CL f Q AUC int u 1 E 1 1 int u int u Dos int u Dos F Q Q CL f Dos CL Q CL f Q CL f CL f int u int u int u

Problm 10 (5 points) 10. Which statmnt is incorrct? A. Cratinin claranc is a masurmnt for kidny function. B. Bioavailability of high xtraction drugs is dpndnt on plasma protin binding. C. Claranc and volum of distribution dtrmin th half-lif of a drug. D. A multi-compartmnt-body modl has only on volum of distribution. E. Changs in claranc affct avrag stady-stat plasma lvls

Problm 11 (10 points) Drug B is administrd via multipl short-trm infusions. Dtrmin an appropriat dosing rgimn for a multipl two-hour infusion (dosing rat (R0) and dosing intrval) of drug B to achiv dsird stady stat plasma concntrations of 12.5 mg/l for th pak (drawn 2 h aftr th nd of a 2 h infusion) and approximatly 3.5 mg/l for th trough. Assum that drug B s plasmaconcntration-tim profil follows a on-compartmnt body modl. (CL = 15 L/h, VD = 100 L). Round appropriatly and us a clinically usd dosing intrval. A. R 0 = 815mg/h Q24h B. R 0 = 1630mg/h Q12h C. R 0 = 1630mg/h Q24h D. R 0 = 815mg/h Q12h E. R 0 = 815mg/h Q8h k = CL VD = 0.15 L h τ = ln(c pak,dsird) ln(c trough,dsird ) k + T + t = 1.27 h + 2h + 2h = 12.47 h (round down to 12 h) 0.15 Dos = C pak,dsird CL T (1 k τ ) (1 k T )( k t ) 12.5 mg L 15 L h 2h (1 0.15h 1 12h ) = 1630 mg in 2 h or 815mg in 1h (1 0.15h 1 2h )( 0.15h 1 2h ) =

Problm 12 (5 points) Slct th incorrct statmnt A. In a on-compartmnt body modl, th volum of distribution dcrass with an incras in plasma protin binding B. In a two compartmnt body modl, th volum of distribution at stady stat (VDSS) is always largr than th volum of distribution of th cntral body compartmnt (Vc) C. Th plasma concntration at stady stat is a function of dosing rat (R0) and claranc (CL) D. In a two compartmnt body modl, VDara is not indpndnt of th claranc (CL) E. For a high xtraction drug, th fr plasma concntration at stady incrass with a dcras in tissu protin binding

Problm 13 (5 points) Which of th following statmnts is/ar tru rgarding cftazidim? (s graph blow). Th graph blow shows th fficacy paramtrs of cftazidim against K. pnumonia infction in nutropnic mic. Th targt lvl for fficacy is 7.2 log10 CFU/Thigh at 24 hours. i. Th ffct profil for this drug is a concntration-dpndnt on. ii. Th tim abov MIC is th paramtr of choic to valuat fficacy of cftazidim against K. pnumonia. iii. Th paramtr valu that achivs th minimum ffct is approximatly 35 hr abov MIC, which corrsponds to th targt valu of 7.2 log10 CFU/Thigh. iv. Th 24-hour AUC/MIC ratio gratr than 1000 is rquird to achiv th ffct of lowring th log10 CFU/Thigh blow 7.2. v. Incrasing th tim abov MIC, pak drug concntration and AUC/MIC ratio rsultd in a dcras in CFU, suggsting that this drug has bactricidal ffct. A. I, IV, V B. II, III, V C. II, III D. II, III, IV, V E. I, III, IV

Problm 14 (5 points) A 45-yar-old fmal patint (50 kg, 5 4, Cp,crat = 1.1 mg/dl,) is tratd with 100 mg gntamicin i.v. short-trm infusions (T = 30 min) Q8h. Assuming linar pharmacokintics (Vd=0.25L/kg, CL=ClCr), prdict th tru pak concntration at th nd of th infusion and th tru trough concntration bfor th nxt infusion at stady stat. A. Cmax: 8.79 mg/l Cmin : 1.41 mg/l B. Cmax: 6.79 mg/l Cmin : 0.85 mg/l C. Cmax: 8.79 mg/l Cmin : 1.85 mg/l D. Cmax: 10.79 mg/l Cmin : 0.85 mg/l E. Cmax: 10.79 mg/l Cmin : 1.41 mg/l IBW fmal = 45.5kg + 2.3kg (64 60) = 54.7kg TBW= 50 (kg) is smallr than IBW*120%, us TBW to calculat th Clcr C max,ss = CL Cr = (140 45) 50 1.1 85 = 50.8 ml min = 3.05 L h k = CL L VD = 3.05 h 1 0.25 L = 0.244 kg 50kg h Dos (1 k T ) VD k T (1 k τ ) = 100mg (1 0.2441 h 0.5h ) 12.5L 0.244 1 = h 0.5h (1 0.2441 h 8h ) 65.57 mg L 0.115 mg = 8.79 0.858 L C min,ss = C max,ss k (τ T) = 8.79 mg L 0.244 1 h 7.5h = 1.41 mg L